BeOne Medicines hits $1.1B in Brukinsa sales as global revenue surges 35%

BeOne Medicines (NASDAQ:ONC) delivered a record-breaking first quarter for 2026, as the global oncology specialist saw its flagship therapy, Brukinsa (zanubrutinib), cement its status as a leading treatment in the BTK inhibitor market.

The company reported total global revenues of $1.5 billion for the period ended March 31, 2026, representing a 35% increase compared to the first quarter of 2025.

The primary driver of the quarter’s success was the continued rapid uptake of Brukinsa, which recorded global revenues of $1.1 billion.

This represents a 38% year-over-year surge, fueled by expanding market share in the United States and Europe following approvals for a broad range of B-cell malignancies.

The treatment’s performance highlights BeOne's ability to compete with legacy pharmaceutical giants in the targeted therapy space.

Profitability metrics also saw a significant boost as the company achieved greater scale across its commercial footprint.

BeOne reported diluted GAAP earnings per American Depository Share (ADS) of $1.96 for the first quarter.

On a non-GAAP basis, which excludes stock-based compensation and certain one-time items, diluted earnings per ADS reached $3.24, reflecting the company’s transition toward sustained profitability.

The company's financial strength is supported by a robust balance sheet, allowing for continued research and development into its solid tumor and hematology programs.